Nothing Special   »   [go: up one dir, main page]

DK2248812T5 - Kondenserede cykliske forbindelser som GPR40-receptormodulatorer - Google Patents

Kondenserede cykliske forbindelser som GPR40-receptormodulatorer Download PDF

Info

Publication number
DK2248812T5
DK2248812T5 DK10172951.5T DK10172951T DK2248812T5 DK 2248812 T5 DK2248812 T5 DK 2248812T5 DK 10172951 T DK10172951 T DK 10172951T DK 2248812 T5 DK2248812 T5 DK 2248812T5
Authority
DK
Denmark
Prior art keywords
receptor modulators
cyclic compounds
condensed cyclic
gpr40 receptor
gpr40
Prior art date
Application number
DK10172951.5T
Other languages
English (en)
Other versions
DK2248812T3 (da
Inventor
Tsuneo Yasuma
Masayuki Yamashita
Nobuyuki Negoro
Masahiro Itou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DK2248812T3 publication Critical patent/DK2248812T3/da
Application granted granted Critical
Publication of DK2248812T5 publication Critical patent/DK2248812T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
DK10172951.5T 2006-06-27 2007-06-26 Kondenserede cykliske forbindelser som GPR40-receptormodulatorer DK2248812T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006177099 2006-06-27
EP07767983A EP2041123B9 (en) 2006-06-27 2007-06-26 Fused cyclic compounds

Publications (2)

Publication Number Publication Date
DK2248812T3 DK2248812T3 (da) 2014-03-10
DK2248812T5 true DK2248812T5 (da) 2015-01-26

Family

ID=38656568

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10172951.5T DK2248812T5 (da) 2006-06-27 2007-06-26 Kondenserede cykliske forbindelser som GPR40-receptormodulatorer
DK07767983.5T DK2041123T3 (da) 2006-06-27 2007-06-26 Kondenserede cykliske forbindelser.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07767983.5T DK2041123T3 (da) 2006-06-27 2007-06-26 Kondenserede cykliske forbindelser.

Country Status (37)

Country Link
US (5) US7732626B2 (da)
EP (4) EP2431367A3 (da)
JP (3) JP4401428B2 (da)
KR (1) KR101058772B1 (da)
CN (4) CN103083307A (da)
AR (1) AR061644A1 (da)
AT (1) ATE543815T1 (da)
AU (1) AU2007265966B2 (da)
BR (1) BRPI0713378A8 (da)
CA (2) CA2838448A1 (da)
CL (1) CL2007001873A1 (da)
CO (1) CO6160234A2 (da)
CR (1) CR10564A (da)
CY (2) CY1112705T1 (da)
DK (2) DK2248812T5 (da)
ES (2) ES2379661T3 (da)
GE (1) GEP20115359B (da)
HK (1) HK1131126A1 (da)
HR (2) HRP20120333T1 (da)
IL (1) IL195947A (da)
JO (1) JO2969B1 (da)
MA (1) MA30537B1 (da)
ME (1) ME00535B (da)
MX (1) MX2008016274A (da)
MY (1) MY154798A (da)
NO (1) NO20090235L (da)
NZ (1) NZ574038A (da)
PE (1) PE20080993A1 (da)
PL (2) PL2248812T3 (da)
PT (2) PT2041123E (da)
RS (2) RS52307B (da)
RU (1) RU2444521C2 (da)
SI (2) SI2248812T1 (da)
TW (1) TWI354668B (da)
UA (1) UA95296C2 (da)
WO (1) WO2008001931A2 (da)
ZA (1) ZA200900154B (da)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0818253A2 (pt) 2007-10-10 2015-04-07 Amgen Inc Moduladores de gpr40 bifenil substituídos
CA2716352C (en) * 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN102137836B (zh) 2008-07-28 2015-08-26 赛丹思科大学 用于治疗代谢疾病的化合物
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
CA2739888C (en) 2008-10-15 2013-11-19 Amgen Inc. Spirocyclic gpr40 modulators
EP2351743A4 (en) 2008-10-27 2012-05-09 Takeda Pharmaceutical BICYCLIC CONNECTION
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8557805B2 (en) 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
AR075158A1 (es) 2009-01-27 2011-03-16 Takeda Pharmaceutical Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos.
KR20120022801A (ko) 2009-04-22 2012-03-12 아스텔라스세이야쿠 가부시키가이샤 카르복실산 화합물
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
KR20120039046A (ko) 2009-07-28 2012-04-24 다케다 야쿠힌 고교 가부시키가이샤 정제
EP2495238A4 (en) 2009-10-30 2013-04-24 Mochida Pharm Co Ltd NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
MA33952B1 (fr) 2009-12-25 2013-01-02 Mochida Pharmacal Co Ltd Nouveau dérivé 3 -hydroxy- 5-arylisothiazole
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN103025716B (zh) 2010-04-27 2014-12-24 武田药品工业株式会社 二环化合物衍生物及其作为acc抑制剂的用途
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
TWI511967B (zh) 2010-06-16 2015-12-11 Takeda Pharmaceutical 醯胺化合物之結晶
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US20130184272A1 (en) 2010-09-17 2013-07-18 Takeda Pharmaceutical Company Limited Diabetes therapeutic agent
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
MX2013006113A (es) 2010-11-30 2013-11-01 Takeda Pharmaceutical Compuestos biciclico.
PL2646425T3 (pl) 2010-12-01 2015-12-31 Boehringer Ingelheim Int Kwasy indanyloksydihydrobenzofuranylooctowe użyteczne do leczenia zespołu metabolicznego
JP5945545B2 (ja) * 2011-02-17 2016-07-05 武田薬品工業株式会社 光学活性なジヒドロベンゾフラン誘導体の製造法
US9499467B2 (en) 2011-04-08 2016-11-22 Caldan Therapeutics Limited Ortho-fluoro substituted compounds for the treatment of metabolic diseases
NZ617409A (en) 2011-04-27 2015-08-28 Mochida Pharm Co Ltd Novel 3-hydroxyisothiazole 1-oxide derivative
CA2834465A1 (en) 2011-04-28 2012-11-01 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103012343B (zh) * 2011-09-26 2015-04-08 上海恒瑞医药有限公司 稠合环类衍生物、其制备方法及其在医药上的应用
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2853221A1 (en) 2011-10-24 2013-05-02 Tohru Yamashita Bicyclic compound
WO2013105676A1 (en) 2012-01-12 2013-07-18 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
BR112014016648B1 (pt) * 2012-01-12 2020-10-27 Shanghai Hengrui Pharmaceutical Co., Ltd. derivados policíclicos, seus usos e seu processo de preparação, e composição farmacêutica
GB2498968A (en) * 2012-02-01 2013-08-07 Prosidion Ltd Pharmaceutical combination of a GPR119 agonist and a GPR40 agonist
WO2013122029A1 (ja) 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
WO2013122028A1 (ja) 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
US20150011549A1 (en) 2012-02-15 2015-01-08 Takeda Pharmaceutical Company Limited Tablet
US9238639B2 (en) 2012-02-24 2016-01-19 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013128378A1 (en) * 2012-02-28 2013-09-06 Piramal Enterprises Limited Phenyl alkanoic acid derivatives as gpr agonists
US8642585B2 (en) * 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
JPWO2013147026A1 (ja) 2012-03-29 2015-12-14 武田薬品工業株式会社 芳香環化合物
US8809376B2 (en) 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
EP2848622A4 (en) 2012-05-10 2015-11-04 Takeda Pharmaceutical AROMATIC RING CONNECTION
WO2013168759A1 (ja) 2012-05-10 2013-11-14 武田薬品工業株式会社 芳香環化合物
TWI580444B (zh) 2012-06-05 2017-05-01 武田藥品工業股份有限公司 固態製劑
JP2015522080A (ja) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6262733B2 (ja) 2012-09-04 2018-01-17 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． イミダゾリン誘導体、その製造法、およびそれらの医薬への適用
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
TWI692469B (zh) 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
CN104812748B (zh) 2012-11-16 2017-10-24 百时美施贵宝公司 二氢吡唑gpr40调节剂
CN104822675A (zh) 2012-11-28 2015-08-05 勃林格殷格翰国际有限公司 新的茚满基氧基二氢苯并呋喃乙酸
EP2928886B1 (en) 2012-12-07 2016-11-02 Boehringer Ingelheim International GmbH New indanyloxydihydrobenzofuranylacetic acids
JP6314335B2 (ja) 2013-02-06 2018-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
JP6387023B2 (ja) * 2013-02-28 2018-09-05 ティウムバイオ カンパニー、リミテッドＴｉｕｍＢｉｏ Ｃｏ．， Ｌｔｄ． 三環式化合物およびその使用
CN103145663B (zh) * 2013-03-01 2016-03-23 上海高准医药有限公司 (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物，其制备方法及其在医药上的应用
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
CN104059039B (zh) * 2013-03-22 2017-03-15 正大天晴药业集团股份有限公司 具有gpr40受体功能调节作用的稠环化合物
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
AR096041A1 (es) 2013-04-17 2015-12-02 Piramal Entpr Ltd Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
WO2014187343A1 (zh) * 2013-05-22 2014-11-27 四川海思科制药有限公司 苯并呋喃衍生物、其制备方法及其在医药上的应用
CN104250238B (zh) * 2013-06-25 2017-12-26 南京圣和药业股份有限公司 Gpr40激动剂及其应用
CN104250239B (zh) * 2013-06-29 2016-09-07 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
WO2015000412A1 (zh) * 2013-07-02 2015-01-08 四川海思科制药有限公司 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
CN105358544A (zh) 2013-07-09 2016-02-24 武田药品工业株式会社 杂环化合物
DK3031799T3 (da) 2013-08-09 2018-05-28 Takeda Pharmaceuticals Co Aromatisk forbindelse
CN104370864B (zh) * 2013-08-14 2016-04-13 成都苑东生物制药股份有限公司 一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙腈化合物和以该化合物制备tak-875药物的方法
CN105246875A (zh) * 2013-09-03 2016-01-13 四川海思科制药有限公司 茚满衍生物及其制备方法和在医药上的应用
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015062486A1 (en) * 2013-10-31 2015-05-07 Sunshine Lake Pharma Co., Ltd. Biphenyl compounds and uses thereof
JP6352415B2 (ja) 2013-11-14 2018-07-04 カディラ・ヘルスケア・リミテッド 新規なヘテロ環化合物
ES2747973T3 (es) 2013-11-15 2020-03-12 Merck Sharp & Dohme Compuestos tricíclicos antidiabéticos
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN105001212B (zh) * 2014-04-16 2018-01-16 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
EP3177287B1 (en) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CN104177320B (zh) * 2014-08-27 2016-03-02 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
WO2016060517A2 (ko) * 2014-10-17 2016-04-21 현대약품 주식회사 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
CN105418563B (zh) * 2015-12-28 2017-11-10 山东大学 Tak‑875类似物及其制备方法与应用
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110312714B (zh) 2017-01-26 2022-12-09 勃林格殷格翰国际有限公司 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
CN110177773B (zh) 2017-01-26 2023-08-25 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
JP7049349B2 (ja) 2017-01-26 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
WO2018146008A1 (en) 2017-02-08 2018-08-16 Boehringer Ingelheim International Gmbh Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
EP3604267A4 (en) 2017-03-31 2020-12-16 Takeda Pharmaceutical Company Limited AROMATIC CONNECTION
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
EP3709995A4 (en) 2017-11-16 2021-04-14 Merck Sharp & Dohme Corp. BICYCLIC ANTIDIABETIC COMPOUNDS
WO2019134984A1 (en) 2018-01-08 2019-07-11 Celon Pharma S.A. 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists
KR102445054B1 (ko) 2018-02-13 2022-09-22 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN110294744A (zh) * 2018-03-21 2019-10-01 中国医学科学院药物研究所 Gpr40受体激动剂、其制法和其药物组合物与用途
EP3768294A4 (en) 2018-03-23 2022-05-04 Carmot Therapeutics, Inc. PROTEIN-COUPLED RECEPTOR MODULATORS
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
EP3650440A4 (en) 2018-08-27 2020-11-25 Scohia Pharma, Inc. BENZOIC ESTER COMPOUND
JP2022503793A (ja) 2018-09-24 2022-01-12 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
WO2020067575A1 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP3925623A4 (en) * 2019-02-13 2022-11-09 Gexval Inc. MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
AU2021216324A1 (en) 2020-02-07 2022-08-25 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
IL296219A (en) 2020-03-25 2022-11-01 Takeda Pharmaceuticals Co Weekly doses of gip receptor agonist peptides and their uses
CA3173129A1 (en) 2020-03-25 2021-09-30 Antoine Charles Olivier HENNINOT Qd dosing of gip receptor agonist peptide compounds and uses thereof
CA3187811A1 (en) 2020-08-12 2022-02-17 Gexval Inc. Pharmaceutical composition for preventing or treating bone diseases
US20240067603A1 (en) * 2020-12-16 2024-02-29 Regents Of The University Of Minnesota Cubanyl biguanide compounds
US20230151074A1 (en) 2021-05-13 2023-05-18 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024138048A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309324D0 (en) * 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
US5612330A (en) 1994-03-07 1997-03-18 Warner-Lambert Company Methods for inhibiting and controlling viral growth
US5489586A (en) 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
RU6023U1 (ru) 1997-01-20 1998-02-16 АО "Автоэлектроника" Устройство управления для экономайзера принудительного холостого хода
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
YU74701A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati tri-aril kiseline kao ligandi ppar receptora
RU11297U1 (ru) 1999-06-16 1999-09-16 Курзанов Евгений Владимирович Установка для выборочного измерения производительности нефтяных источников при групповом учете
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2383257C (en) 1999-08-26 2010-09-28 Christopher J. Burns Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
AU7556800A (en) 1999-10-07 2001-05-10 Tadeka Chemical Industries, Ltd. Amine derivatives
HUP0203165A3 (en) 1999-11-10 2004-03-29 Takeda Pharmaceutical 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US7005430B2 (en) * 1999-12-24 2006-02-28 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
US6930185B2 (en) 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
RU2340611C2 (ru) 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
WO2002022606A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030096249A1 (en) 2000-12-21 2003-05-22 Westphal Ryan S. Nucleic acid molecules and polypeptides for a human cation channel polypeptide
EP2264028A1 (en) 2000-12-21 2010-12-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EE200300470A (et) 2001-03-30 2004-02-16 Pfizer Products Inc. Aldoosreduktaasi püridasinooninhibiitorid
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
TW522326B (en) * 2001-08-03 2003-03-01 Inventec Corp Real-time data customer service system and method thereof
US6701066B2 (en) * 2001-10-11 2004-03-02 Micron Technology, Inc. Delivery of solid chemical precursors
US20050245571A1 (en) 2001-10-19 2005-11-03 Hidenori Abe Amine derivative
JP4166024B2 (ja) 2002-03-07 2008-10-15 独立行政法人科学技術振興機構 ２環式化合物およびその製造方法
JP4091600B2 (ja) 2002-04-26 2008-05-28 エフ．ホフマン−ラ ロシュ アーゲー 置換フェニルアセトアミド及びグルコキナーゼ活性化物質としてのその使用
WO2004011469A1 (ja) * 2002-07-26 2004-02-05 Kyowa Hakko Kogyo Co., Ltd. 細胞分化誘導剤
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
JPWO2004080943A1 (ja) * 2003-03-11 2006-06-08 小野薬品工業株式会社 シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US7820837B2 (en) * 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
RU2353617C2 (ru) 2003-10-31 2009-04-27 Такеда Фармасьютикал Компани Лимитед Производные пиридина в качестве ингибиторов дипептидилпептидазы iv
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) * 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
US7786165B2 (en) * 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
WO2005095338A1 (ja) * 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
JP3689711B1 (ja) 2004-12-24 2005-08-31 極東鋼弦コンクリート振興株式会社 真空グラウト注入方法
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
AU2006217677A1 (en) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
TW200811170A (en) * 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
TW200811158A (en) * 2006-06-27 2008-03-01 Sanofi Aventis Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application

Also Published As

Publication number Publication date
PE20080993A1 (es) 2008-10-06
CN102731451B (zh) 2015-07-29
CN101616913A (zh) 2009-12-30
US20100197761A1 (en) 2010-08-05
JP5409757B2 (ja) 2014-02-05
EP2743268A2 (en) 2014-06-18
RS53230B (en) 2014-08-29
DK2248812T3 (da) 2014-03-10
RU2444521C2 (ru) 2012-03-10
CN103070854A (zh) 2013-05-01
IL195947A0 (en) 2009-09-01
DK2041123T3 (da) 2012-05-07
JP2009280595A (ja) 2009-12-03
EP2041123A2 (en) 2009-04-01
US20120046338A1 (en) 2012-02-23
CN102731451A (zh) 2012-10-17
ME00535B (me) 2011-10-10
CN103083307A (zh) 2013-05-08
EP2041123B9 (en) 2013-01-02
US7732626B2 (en) 2010-06-08
EP2248812A2 (en) 2010-11-10
CA2838448A1 (en) 2008-01-03
US20130267589A1 (en) 2013-10-10
EP2743268A3 (en) 2014-10-08
MA30537B1 (fr) 2009-06-01
PT2041123E (pt) 2012-04-09
AU2007265966B2 (en) 2012-05-17
EP2431367A2 (en) 2012-03-21
EP2431367A3 (en) 2012-07-04
US8088821B2 (en) 2012-01-03
PT2248812E (pt) 2014-03-12
ZA200900154B (en) 2010-03-31
CN101616913B (zh) 2013-01-23
CA2656003C (en) 2014-03-25
RS52307B (en) 2012-12-31
CY1112705T1 (el) 2016-02-10
JP4401428B2 (ja) 2010-01-20
MY154798A (en) 2015-07-31
TWI354668B (en) 2011-12-21
CO6160234A2 (es) 2010-05-20
US20140080891A1 (en) 2014-03-20
RU2009102515A (ru) 2010-08-10
HRP20140201T1 (hr) 2014-04-11
EP2041123B1 (en) 2012-02-01
PL2248812T3 (pl) 2014-07-31
CA2656003A1 (en) 2008-01-03
JP2009542580A (ja) 2009-12-03
WO2008001931A3 (en) 2009-09-11
NZ574038A (en) 2011-12-22
US8598226B2 (en) 2013-12-03
AU2007265966A1 (en) 2008-01-03
TW200811125A (en) 2008-03-01
US8492430B2 (en) 2013-07-23
CY1114978T1 (el) 2016-12-14
BRPI0713378A2 (pt) 2012-04-03
ATE543815T1 (de) 2012-02-15
GEP20115359B (en) 2011-12-26
WO2008001931A2 (en) 2008-01-03
SI2248812T1 (sl) 2014-04-30
HK1131126A1 (en) 2010-01-15
CR10564A (es) 2012-06-18
HRP20120333T1 (hr) 2012-05-31
CL2007001873A1 (es) 2008-01-04
MX2008016274A (es) 2009-01-15
BRPI0713378A8 (pt) 2018-01-02
ES2450081T3 (es) 2014-03-21
AR061644A1 (es) 2008-09-10
US20100004312A1 (en) 2010-01-07
PL2041123T3 (pl) 2012-09-28
UA95296C2 (uk) 2011-07-25
JP4917634B2 (ja) 2012-04-18
JP2012062320A (ja) 2012-03-29
JO2969B1 (en) 2016-03-15
KR101058772B1 (ko) 2011-08-24
KR20090027743A (ko) 2009-03-17
ES2379661T3 (es) 2012-04-30
EP2248812B1 (en) 2013-12-25
NO20090235L (no) 2009-02-16
EP2248812A3 (en) 2011-03-16
SI2041123T1 (sl) 2012-05-31
IL195947A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
DK2248812T5 (da) Kondenserede cykliske forbindelser som GPR40-receptormodulatorer
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
BRPI0818253A2 (pt) Moduladores de gpr40 bifenil substituídos
DK1928845T3 (da) Aminodiazepiner som toll-lignende receptor-modulatorer
BRPI0813653A2 (pt) Compostos de imidazotiazol moduladores de sirtuína
BRPI0813651A2 (pt) Compostos de tiazolopiridina moduladores de sirtuína
DK2952177T3 (da) Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
DK2069335T3 (da) Pyridin-3-ylderivater som immunomoduleringsmidler
DK2144897T3 (da) 8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer
DK2528930T3 (da) 4'-azido-nukleosider som anti-hcv-forbindelser
BRPI0720972A2 (pt) análogos de ciclopamina
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
NL2000581A1 (nl) Aangecondenseerde fenylamidoheterocyclische verbindingen.
BRPI0921815A2 (pt) compostos receptores de apj
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
BRPI0819093A2 (pt) compostos moduladores de sirtuína
BRPI0823379A2 (pt) Análogos de glucagon
BRPI0823377A2 (pt) análogos de glucagon
BRPI0823378A2 (pt) análogos de glucagon
BRPI0823376A2 (pt) Análagos de glucagon
DK2331530T3 (da) Kondenserede multicycliske forbindelser som proteinkinaseinhibitorer
DK2411393T3 (da) Kondenserede pyrimidin-dionderivater som TRPA1-modulatorer
DE602007011793D1 (de) Biaryl-ether-harnstoffverbindungen
BRPI0815042A2 (pt) Compostos de pirazol
DK2291368T3 (da) Substitueret gamma-lactam som terapeutisk middel